S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IMMX · Immix Biopharma, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Immix Biopharma Inc (IMMX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$8.50
-0.43
(-4.82%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$8.50
$8.47
$9.07
52-WEEK RANGE
$8.50
$2.71
$15.10
What's happening
- IMMX is down 4.82% today, trading at $8.50. — Live quote
- Volume today (141,752) is well below its 3-month average of 1,787,610. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.18 actual vs. $-0.18 estimated (-0.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IMMX
+70.36%
vs S&P 500
+57.59%
1-YEAR RETURN
IMMX
+190.23%
vs S&P 500
+175.67%
6-MONTH RETURN
IMMX
-10.54%
3-MONTH RETURN
IMMX
-6.90%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.18
Est. $-0.18
MISS -0.4%
2026-04-26 (Q1 2026)
$-0.18
Est. $-0.21
BEAT +15.3%
2026-01-26 (Q4 2025)
$-0.28
Est. $-0.16
MISS -76.0%
2025-10-26 (Q3 2025)
$-0.24
Est. $-0.19
MISS -23.8%
Valuation Measures & Ratios
Enterprise Value4$480.0M
Forward P/E5—
PEG Ratio6-0.90
Price / Sales (TTM1)—
Price / Book73.14
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-38.44%
Return on Assets (ROA9)-34.72%
Avg Volume (3M)1,787,610
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $660.7M | $511.6M | $66.1M | $62.9M | $51.5M |
| P/E | -18.43 | -17.74 | -2.55 | -2.77 | -2.41 |
| Price/Book | 2.89 | 6.06 | — | 13.52 | 5.37 |
| ROE | -15.66% | -34.18% | — | -488.01% | -222.48% |
| ROA | -14.99% | -30.10% | -128.98% | -145.23% | -107.30% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short10,390,288
Change from Prior Settlement+7.99%
% of Float—
Days to Cover (Short Ratio)5.11
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +190.2%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-09-30; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IMMX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$12.5M | -$10.8M | -$7.7M | -$6.7M | -$4.7M | -$7.4M | -$4.7M | -$5.6M |
| Net income | -$11.6M | -$10.1M | -$7.6M | -$6.6M | -$4.5M | -$7.1M | -$4.4M | -$5.3M |
| EPS (diluted) | $-0.18 | $-0.18 | $-0.24 | $-0.22 | $-0.15 | $-0.24 | $-0.15 | $-0.22 |
| EPS (basic) | $-0.18 | $-0.18 | $-0.24 | $-0.22 | $-0.15 | $-0.24 | $-0.15 | $-0.22 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $239.1M | $95.8M | $104.8M | $20.1M | $15.6M | $19.9M | $22.9M | $25.1M |
| Total liabilities | $10.2M | $11.5M | $11.0M | $11.8M | $11.0M | $10.3M | $9.7M | $7.6M |
| Stockholders' equity | $228.9M | $84.4M | $93.8M | — | $4.7M | $9.6M | $13.3M | $17.6M |
| Total current assets | $233.8M | $92.3M | $101.2M | $16.6M | $12.3M | $16.8M | $20.2M | $22.8M |
| Total current liabilities | $9.3M | $10.5M | $10.1M | $10.9M | $10.0M | $9.3M | $8.7M | $6.6M |
| Cash & equivalents | $225.5M | $79.3M | $93.9M | $15.9M | $11.6M | $15.9M | $17.7M | $19.7M |
| Marketable securities (current) | $6.6M | $11.3M | $6.5M | — | — | — | — | — |
| Other current assets | $279.2K | $335.7K | $150.7K | $132.8K | $137.7K | $168.4K | $32.3K | $36.5K |
| Marketable securities (non-current) | $2.1M | — | — | — | — | — | — | — |
| Property, plant & equipment | $2.4M | $2.4M | $2.5M | $2.4M | $2.2M | $2.1M | $1.7M | $1.4M |
| Other non-current assets | $20.4K | $20.4K | $20.4K | $20.4K | $20.4K | $20.4K | $20.4K | $20.4K |
| Accounts payable | $5.3M | $4.7M | $5.4M | $7.1M | $6.6M | $5.7M | $5.4M | $3.3M |
| Common stock & paid-in capital | $7.2K | $5.3K | $5.3K | $3.3K | $2.8K | $2.8K | $2.8K | $2.8K |
| Retained earnings | -$126.1M | -$114.5M | -$104.5M | -$93.8M | -$86.2M | -$79.6M | -$75.0M | -$70.2M |
| Accumulated other comprehensive income (loss) | $118.7K | $105.6K | $60.2K | $62.5K | $65.0K | $15.5K | -$1.1K | $192.1K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.7M | -$9.8M | -$11.0M | -$5.9M | -$5.3M | -$1.7M | -$1.5M | -$4.0M |
| Investing cash flow | $2.7M | -$4.8M | -$6.6M | -$372.5K | -$127.6K | -$67.7K | -$507.2K | -$271.5K |
| Financing cash flow | $155.3M | -$37.6K | $95.7M | $10.6M | $1.1M | — | $0 | $0 |
| Free cash flow | -$11.8M | -$9.9M | -$11.2M | -$6.3M | -$5.4M | -$1.8M | -$2.0M | -$4.3M |
| Capital expenditures | $21.0K | $32.5K | $165.1K | $372.5K | $127.6K | $67.7K | $507.2K | $271.5K |
| Share-based compensation | $978.1K | $575.6K | $570.8K | $470.5K | $532.2K | $868.4K | $705.7K | $733.8K |
| Purchases of investments | $12.3M | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M |
| EPS (diluted) | $-0.89 | $-0.76 | $-0.89 | $-0.59 | — |
| EPS (basic) | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-6.64 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202.0K |
| Stockholders' equity | — | $13.3M | $16.4M | $13.2M | $18.0M |
| Total current assets | $101.2M | $20.2M | $19.8M | $14.9M | $18.2M |
| Total current liabilities | $10.1M | $8.7M | $3.7M | $1.3M | $202.0K |
| Cash & equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M |
| Marketable securities (current) | $6.5M | — | — | — | — |
| Other current assets | $150.7K | $32.3K | $44.6K | $78.1K | — |
| Property, plant & equipment | $2.5M | $1.7M | $50.2K | $3.6K | $5.7K |
| Other non-current assets | $20.4K | $20.4K | — | $6.7K | — |
| Accounts payable | $5.4M | $5.4M | $1.4M | $143.1K | — |
| Common stock & paid-in capital | $5.3K | $2.8K | $2.0K | $1.4K | $1.3K |
| Retained earnings | -$104.5M | -$75.0M | -$53.4M | -$38.0M | -$29.8M |
| Accumulated other comprehensive income (loss) | $60.2K | -$1.1K | $134.7K | $87.0K | $125.4K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M |
| Investing cash flow | -$7.2M | -$1.2M | -$52.1K | — | -$802 |
| Financing cash flow | $107.4M | $15.9M | $15.5M | $3.2M | $18.8M |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | — | -$1.6M |
| Capital expenditures | $732.9K | $1.2M | $52.1K | — | $802 |
| Share-based compensation | $2.4M | $3.0M | $2.6M | $624.1K | $219.0K |
| Share repurchases | — | — | — | $100.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IMMX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers82.3%
Shares Outstanding63,771,377
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 9,783,192 | $100.8M | 15.34% | +0.0% | 2026-08-14 |
| Saturn V Capital Management LP | 4,658,429 | $48.0M | 7.30% | +26.1% | 2026-08-14 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3,891,019 | $40.1M | 6.10% | +52.6% | 2026-08-14 |
| State Street Corp | 2,996,935 | $30.9M | 4.70% | +1461.6% | 2026-08-07 |
| BlackRock, Inc. | 2,989,972 | $30.8M | 4.69% | +538.4% | 2026-08-07 |
| Deep Track Capital, LP | 2,775,000 | $28.6M | 4.35% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,507,122 | $25.8M | 3.93% | +40.2% | 2026-06-30 |
| Opaleye Management Inc. | 2,345,000 | $24.2M | 3.68% | +0.0% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 2,066,426 | $21.3M | 3.24% | +18.1% | 2026-08-14 |
| UBS Group AG | 1,941,817 | $20.0M | 3.04% | +2427.4% | 2026-08-13 |
| MARSHALL WACE, LLP | 1,794,908 | $18.5M | 2.81% | +9.3% | 2026-08-13 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,739,919 | $17.9K | 2.73% | +319.3% | 2026-08-14 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,473,409 | $15.2M | 2.31% | +0.0% | 2026-08-14 |
| GREAT POINT PARTNERS LLC | 1,277,642 | $13.2M | 2.00% | +265.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,201,097 | $12.4M | 1.88% | +159.2% | 2026-08-12 |
| Velan Capital Investment Management LP | 1,085,000 | $11.2M | 1.70% | +46.6% | 2026-08-14 |
| Bleichroeder LP | 1,000,000 | $10.3M | 1.57% | +0.0% | 2026-08-13 |
| Logos Global Management LP | 1,000,000 | $10.3M | 1.57% | -18.4% | 2026-08-14 |
| Franklin Templeton Inc | 969,120 | $10.0M | 1.52% | +0.0% | 2026-08-04 |
| Burkehill Global Management, LP | 544,118 | $5.6M | 0.85% | +85.0% | 2026-08-14 |
| Ameriprise Financial Inc | 518,881 | $5.3M | 0.81% | +0.0% | 2026-08-14 |
| CITADEL ADVISORS LLC | 506,157 | $5.2M | 0.79% | +973.0% | 2026-08-14 |
| Blue Owl Capital Holdings LP | 437,552 | $4.5M | 0.69% | -20.1% | 2026-08-11 |
| Northern Trust Corp | 418,051 | $4.3M | 0.66% | +202.4% | 2026-08-12 |
| BALYASNY ASSET MANAGEMENT L.P. | 417,227 | $4.3M | 0.65% | +0.0% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-12-20 to 2026-05-22
Recent transactions
- Most recent: Adams Helen C. (Director) — Grant / award of 6,250 shares on 2026-05-22.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Adams Helen C. | Director | Grant / award | 2026-05-22 | 6,250 |
| Ng Carey | Director | Grant / award | 2026-05-22 | 6,250 |
| Marquet Magda | Director | Grant / award | 2026-05-22 | 6,250 |
| CHANG NANCY T | Director | Grant / award | 2026-05-22 | 6,250 |
| Chudnovsky Yekaterina | Director | Grant / award | 2026-05-22 | 6,250 |
| Hsu Jason | Director | Grant / award | 2026-05-22 | 6,250 |
| BUCHAN JANE | Director | Grant / award | 2026-05-22 | 6,250 |
| Rachman Ilya M | CEO and Chairman | Open market purchase | 2025-12-10 | 746 |
| Morris Gabriel S | CFO | Open market purchase | 2025-12-10 | 770 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-22 | Adams Helen C. | Director | Grant / award | 6,250 | $0.00 |
| 2026-05-22 | Ng Carey | Director | Grant / award | 6,250 | $0.00 |
| 2026-05-22 | Marquet Magda | Director | Grant / award | 6,250 | $0.00 |
| 2026-05-22 | CHANG NANCY T | Director | Grant / award | 6,250 | $0.00 |
| 2026-05-22 | Chudnovsky Yekaterina | Director | Grant / award | 6,250 | $0.00 |
| 2026-05-22 | Hsu Jason | Director | Grant / award | 6,250 | $0.00 |
| 2026-05-22 | BUCHAN JANE | Director | Grant / award | 6,250 | $0.00 |
| 2025-12-10 | Rachman Ilya M | CEO and Chairman | Open market purchase | 746 | $6.67 |
| 2025-12-10 | Morris Gabriel S | CFO | Open market purchase | 770 | $6.58 |
| 2025-12-08 | Morris Gabriel S | CFO | In-the-money option exercise | 156,000 | $0.80 |
| 2025-09-17 | Rachman Ilya M | CEO and Chairman | Open market purchase | 2,500 | $2.02 |
| 2025-09-16 | Morris Gabriel S | CFO | Open market purchase | 2,600 | $1.97 |
| 2025-06-18 | Rachman Ilya M | CEO and Chairman | Open market purchase | 2,178 | $2.29 |
| 2025-06-18 | Morris Gabriel S | CFO | Open market purchase | 2,225 | $2.28 |
| 2024-12-23 | Hsu Jason | Director | Open market purchase | 40,000 | $2.19 |
| 2024-12-20 | Hsu Jason | Director | Open market purchase | 7,700 | $2.17 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:32 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-30 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-20 | 8-K | 2026-07-20 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-22 | View on SEC.gov → |
Recent news
Headlines about IMMX (Immix Biopharma, Inc.). Links open the publisher — we don’t host full articles.
-
Immix Biopharma, Inc. (IMMX) Stock Price, News, Quote & History
Yahoo Finance · 2026-10-21 -
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
Yahoo · 2026-10-21 -
Morgan Stanley initiates Immix Biopharma stock with overweight rating
Investing.com · 2026-10-20 -
How IMMX Group (IMMX) Affects Rotational Strategy Timing
Stock Traders Daily · 2026-10-18 -
Immix Biopharma, Inc. (IMMX) Stock Price Prediction for 2026, 2030-2040
Traders Union · 2026-10-17 -
Immix Biopharma Stock Price Forecast. Should You Buy IMMX?
StockInvest.us · 2026-10-16 -
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Yahoo Finance · 2026-10-05 -
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Yahoo Finance · 2026-10-05
No headlines in this category right now — try “All”.